TL;DR
Comparing the two research forms of CJC-1295 — DAC (drug affinity complex) and No DAC — for pharmacokinetic and research protocol considerations.
Research use only. This guide summarizes published research methodology for educational purposes. All Aureum Peptides products are sold strictly for in-vitro laboratory research.
Native GHRH Limitation
Endogenous GHRH has a ~7 minute plasma half-life due to DPP-IV enzymatic cleavage. This severely limits research utility for any protocol examining sustained somatotropic stimulation.
No DAC Modification
CJC-1295 No DAC incorporates four amino acid substitutions that confer DPP-IV resistance without adding bulk. Plasma half-life extends to ~30 minutes — suitable for acute somatotropic research protocols.
DAC Modification
DAC (Drug Affinity Complex) variant adds a maleimidopropionic acid group that covalently binds to serum albumin via a cysteine thiol, further extending half-life to approximately 6–8 days. Suitable for chronic administration research designs.
Research Selection Logic
Short pharmacodynamic studies (GH pulse characterization, receptor internalization): No DAC. Chronic administration studies (IGF-1 sustained elevation, tissue adaptation): DAC. Combination with Ipamorelin typically uses No DAC for matched kinetics.
Measurement Considerations
Albumin-bound DAC form requires different assay considerations than free No DAC peptide — free vs total peptide measurements diverge significantly. Consult specific assay protocols.
Research-Grade Material from Aureum
Aureum Peptides provides research-grade peptides with ≥99% HPLC-verified purity and batch-specific Certificate of Analysis. Same-day dispatch on qualified orders placed before 2:00 PM EST.
Related guides:
Disclaimer: Educational content for qualified researchers. Not research information. No therapeutic claims. Peptides not approved by FDA for human use. For in-vitro laboratory research purposes only.
Last reviewed: 2026-04-21
